Compare Medpace Holdings Inc (MEDP) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Medpace Holdings Inc trades at $530.22 (market cap $15.08B), while YieldMax NVDA Option Income Strategy ETF trades at $12.6. The key difference: Medpace Holdings Inc is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| MEDP | NVDY | |
|---|---|---|
Market Cap | $15.08B | — |
Sector | Technology | Income / Options Overlay |
52-Week High | $620.59 | $17.96 |
52-Week Low | $308.88 | $12.03 |
Enterprise Value | $14.55B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
NVDY trades at $12.41, up 0.4% on the day, with a bearish technical signal from moving averages and a neutral stance from oscillators. The fund generates weekly dividends, with recent payouts ranging from $0.10 to $0.21 per share. News coverage highlights the trade-off between income and potential upside capture relative to NVIDIA's stock performance.
The outlook hinges on investor preference for consistent income versus capital appreciation. Risks include underperformance versus NVIDIA during strong rallies and fee drag. Sentiment is mixed, with some questioning the strategy's long-term value amid NVIDIA's volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
